NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Sample GSM857733 Query DataSets for GSM857733
Status Public on Jan 09, 2012
Title 84.d0
Sample type protein
 
Source name serum
Organism Homo sapiens
Characteristics donor id: 84
vaccination status: previoulsy vaccinated
skin take: yes
nih clinical trial #: 0002-007
time: d0
vaccine type: DVX
vaccine dilution: 1:5 dilution
Treatment protocol n/a
Growth protocol n/a
Extracted molecule protein
Extraction protocol serum samples
Label biotin
Label protocol Biotinylated anti-human IgG (Jackson) was used as secondary antibody followed after washing in T-TBS by streptavidin-PBXL3 conjugate (Martek Biosciences), both at 1/200 in blocking buffer.
 
Hybridization protocol Human sera were used at 1/100 dilution in protein array blocking buffer (Whatman) containing E. coli lysate (Antigen Discovery Inc, Irvine CA) to a final concentration of 10mg/ml protein to block anti-E. coli antibodies. Sera were preincubated at RT for 30 minutes with constant mixing prior to applying to the arrays in triplicate and incubating overnight at 4oC with gentle agitation. After washing in TBS + 0.05% Tween 20% (T-TBS), biotinylated anti-human IgG (Jackson) was used as secondary antibody followed after washing in T-TBS by streptavidin-PBXL3 conjugate (Martek Biosciences), both at 1/200 in blocking buffer.
Scan protocol After washing five times, slides were air dried by brief centrifugation and then scanned and analyzed using a Perkin Elmer ScanArray Express HT microarray scanner (PerkinElmer). Fluorescence intensities were quantified from tiff images by using ProScanArray Express software (PerkinElmer).
Description References:
Baldi, P., and Hatfield, G.W. (2002). DNA Microarrays and Gene Expression: From Experiments to Data Analysis and Modeling. Cambridge University Press
Baldi, P., and Long, A.D. (2001). A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes. Bioinformatics 17, 509-519.
Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Roy. Statist. Soc. Ser. B 57, 289--300.
Hermanson, G., Chun, S., Felgner, J., Tan, X., Pablo, J., Nakajima-Sasaki, R., Molina, D.M., Felgner, P.L., Liang, X., and Davies, D.H. (2011). Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax((R)) using proteome microarrays and development of recombinant protein ELISAs. Vaccine 30, 614-625.
Long, A.D., Mangalam, H.J., Chan, B.Y., Tolleri, L., Hatfield, G.W., and Baldi, P. (2001). Improved statistical inference from DNA microarray data using analysis of variance and a Bayesian statistical framework. Analysis of global gene expression in Escherichia coli K12. J Biol Chem 276, 19937-19944.
Data processing Data analysis was performed using the R (http://www.r-project.org) statistical software. In order to stabilize the variance observed in microarray signals, the vsn normalization was implemented as part of the Bioconductor suite (www.bioconductor.org) to the quantified array intensities using the 'no DNA' spots (IVTT reactions lacking the template DNA) as normalization controls. Inter-group comparisons were performed using a Bayes regularized t-test adapted from Cyber-T for protein arrays (Baldi and Hatfield, 2002; Baldi and Long, 2001). To account for multiple comparison conditions, p-values were corrected by the Benjamini and Hochberg (pBH) method to control the false discovery rate (Benjamini and Hochberg, 1995). After correction, p-values < 0.05 were considered significant. An individual was defined as a responder if the ratio of retransformed signal intensities before and after DVX vaccination (d28/d0) was >2.0 for 2 or more of 6 signature antigens (WR101/H3L, WR113/D8L, WR148, WR150/A27L, WR070/I1L, and WR118/D13L). Seroprevalence rates on d0 and d28 were determined for each antigen based on a cut off defined as the averaged+2SD of the naïve take population (n=50). Individuals positive for one or more of the 6 signature antigens were considered seropositive.
 
Submission date Jan 09, 2012
Last update date Jan 09, 2012
Contact name David Huw Davies
E-mail(s) ddavies@uci.edu
Phone 949 824 7387
Organization name University of California Irvine
Department Medicine
Lab Division of Infectious Diseases
Street address Med Surge II
City Irvine
State/province CA
ZIP/Postal code 92697
Country USA
 
Platform ID GPL15100
Series (1)
GSE34931 Antibody profiling of smallpox vaccinees with/without a 'take' using custom vaccinia virus proteome microarrays

Data table header descriptions
ID_REF
VALUE Array signal intensity after vsn log-transformation and normalization against the no DNA controls.

Data table
ID_REF VALUE
001/C23L 10.33067779
004/C22L 10.44220342
008/C19L 10.60555905
009/C11R 10.99166545
010/C10L 10.49793022
011/- 10.53259009
017/- 10.39589431
018/- 10.38566189
019/C9L 10.22543125
020/C8L 10.67650282
021/C7L 10.53123384
022/C6L 10.33297353
023/C5L 10.29865169
024/C4L 10.83846094
025/C3L 10.31641187
026/C2L 10.53430143
027/C1L 10.52844595
028/N1L 10.6449692
029/N2L 9.895732849
030/M1L 10.2347565

Total number of rows: 200

Table truncated, full table size 3 Kbytes.




Supplementary data files not provided
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap